The Conversation (0)
Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Mar. 16, 2018 08:40AM PST
Pharmaceutical InvestingNovelion Therapeutics (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017 and provided an overview of recent business activities. As quoted in the press release: Chief Operating Officer Jeff Hackman said, “We are …
Novelion Therapeutics (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017 and provided an overview of recent business activities.
As quoted in the press release:
Chief Operating Officer Jeff Hackman said, “We are focused on executing near-term plans that we believe will position our company for sustainable future growth. These priorities include cost control and expense management, reviewing our holding and capital structure with a view toward optimizing our assets for shareholders, advancing the metreleptin development program, and continuing to provide important therapies to our patients.”
